Johnson & Johnson Presents Positive Phase 3 Results for Apalutamide in Prostate Cancer Treatment

Johnson & Johnson presented final results of phase 3 study Proteus, showing that treatment with apalutamide, an androgen receptor inhibitor, associated with androgen deprivation therapy (ADT), administered for six months before and after surgical intervention for prostate cancer, leads to significant improvement in main short-term and long-term clinical outcomes

Romanian Guarantee Fund Launches Selection Process for Financial Intermediaries

FNGCIMM is launching a selection process for financial intermediaries to implement the ‘Garanția de portofoliu din fonduri proprii – FNGCIMM’ product, which aims to extend access to financing for small and medium-sized enterprises, liberal professions, farmers, agricultural associations, and startups